A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of isch
Clinical Trial Grant
Administered By
Neurology, Stroke and Vascular Neurology
Awarded By
Bayer Healthcare Pharmaceuticals Inc
Start Date
February 21, 2023
End Date
December 31, 2027
Administered By
Neurology, Stroke and Vascular Neurology
Awarded By
Bayer Healthcare Pharmaceuticals Inc
Start Date
February 21, 2023
End Date
December 31, 2027